ACLY抑制剂在制备免疫检查点抑制剂抗肿瘤增敏剂中的应用
By combining ACLY inhibitors with immune checkpoint inhibitors, the problem of tumor tolerance to immune checkpoint inhibitors has been solved, the therapeutic effect of tumors has been enhanced, and the sensitivity of tumors to immune checkpoint inhibitors has been increased.
CN117338942BActive Publication Date: 2026-07-17ANHUI PROVINCIAL HOSPITAL
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ANHUI PROVINCIAL HOSPITAL
- Filing Date
- 2023-09-27
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Some tumors are resistant to immune checkpoint inhibitors, which limits their application in tumor treatment. Existing technologies are unable to effectively overcome this resistance mechanism.
Method used
The combination of ACLY inhibitors and immune checkpoint inhibitors, with ACLY inhibitors selected from bepadicarbates, SB 204990, NDI-091143, BMS-303141, small interfering RNAs or short hairpin RNAs targeting the ACLY gene, enhances the sensitivity of tumors to immune checkpoint inhibitors.
Benefits of technology
It significantly improved the therapeutic effect of immune checkpoint inhibitors on resistant tumors, enhanced the immune infiltration of CD8+ T cells, and increased the sensitivity of tumor treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN117338942B_ABST
Abstract
本发明提供一种治疗对免疫检查点抑制剂耐受肿瘤的药物，包括ACLY抑制剂和免疫检查点抑制剂。所述ACLY抑制剂选自贝派地酸、SB 204990、NDI‑091143、BMS‑303141、靶向ACLY基因的小干扰RNA、靶向ACLY基因短发夹RNA中的一种或几种。该药物对免疫检查点抑制剂耐受肿瘤的治疗效果好。
Need to check novelty before this filing date? Find Prior Art